Cases & Deals

  • Home
  • Practices
  • Celgene defends its patent covering pomalidomide and dexamethasone in EP opposition proceedings

Share

Celgene defends its patent covering pomalidomide and dexamethasone in EP opposition proceedings

July 2015

Client(s) Celgene Corporation

Jones Day represents Celgene Corporation in opposition proceedings initiated by six generic companies regarding a Celgene European patent covering pomalidomide and dexamethasone.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.